PCSK9抑制在SARS-CoV-2感染炎症期的作用
本研究为双盲、安慰剂对照、多中心试点试验,纳入60例重症COVID-19伴磨玻璃影肺炎且动脉血氧分压/吸入氧浓度比≤300 mmHg的住院患者,1:1随机接受单次140 mg皮下注射依洛尤单抗或安慰剂。主要终点为30天内死亡或需插管,PCSK9抑制组发生率低于安慰剂组(23.3% vs 53.3%,风险差-30%,95%CI -53.40%至-6.59%),且血清IL-6随时间下降更明显(30天降幅-56% vs -21%)。
要点
- 重症COVID-19炎症期PCSK9抑制可降低30天死亡或插管风险。
- PCSK9抑制组血清IL-6下降幅度大于安慰剂组。
- 基线IL-6高于中位数的患者从PCSK9抑制中生存获益更明显。
核心结论
- 与安慰剂相比,PCSK9抑制降低了重症COVID-19患者30天死亡或需插管的主要终点及IL-6水平。
- 随机化时炎症更强烈的患者接受PCSK9抑制后生存更好,提示炎症强度可能驱动治疗获益。
研究设计与样本
- 双盲、安慰剂对照、多中心试点试验,纳入60例重症COVID-19住院患者,伴磨玻璃影肺炎且动脉血氧分压/吸入氧浓度比≤300 mmHg。
- 患者1:1随机接受单次140 mg皮下注射依洛尤单抗或安慰剂。
- 主要终点为30天内死亡或需插管;主要次要终点为基线至7天和30天循环IL-6变化。
主要发现
- PCSK9抑制组30天内死亡或需插管发生率为23.3%,安慰剂组为53.3%,风险差-30%(95%CI -53.40%至-6.59%)。
- PCSK9抑制组血清IL-6随时间低于安慰剂组,30天降幅分别为-56%和-21%。
- 基线IL-6高于中位数的患者中,PCSK9抑制组死亡率低于安慰剂组,风险差-37.50%(95%CI -68.20%至-6.70%)。
临床怎么用
- 在重症COVID-19炎症期,可考虑PCSK9抑制作为潜在治疗策略,尤其对炎症标志物(如IL-6)升高者。
- 该结果来自小样本试点试验,需更大规模研究验证后方可常规临床应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The intensity of inflammation during COVID-19 is related to adverse outcomes. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in low-density lipoprotein receptor homeostasis, with potential influence on vascular inflammation and on COVID-19 inflammatory response. OBJECTIVES: The goal of this study was to investigate the impact of PCSK9 inhibition vs placebo on clinical and laboratory outcomes in patients with severe COVID-19. METHODS: In this double-blind, placebo-controlled, multicenter pilot trial, 60 patients hospitalized for severe COVID-19, with ground-glass opacity pneumonia and arterial partial oxygen pressure to fraction of inspired oxygen ratio ≤300 mm Hg, were randomized 1:1 to receive a single 140-mg subcutaneous injection of evolocumab or placebo. The primary endpoint was death or need for intubation at 30 days. The main secondary endpoint was change in circulating interleukin (IL)-6 at 7 and 30 days from baseline. RESULTS: Patients randomized to receive the PCSK9 inhibitor had lower rates of death or need for intubation within 30 days vs placebo (23.3% vs 53.3%, risk difference: -30%; 95% CI: -53.40% to -6.59%). Serum IL-6 across time was lower with the PCSK9 inhibitor than with placebo (30-day decline: -56% vs -21%). Patients with baseline IL-6 above the median had lower mortality with PCSK9 inhibition vs placebo (risk difference: -37.50%; 95% CI: -68.20% to -6.70%). CONCLUSIONS: PCSK9 inhibition compared with placebo reduced the primary endpoint of death or need for intubation and IL-6 levels in severe COVID-19. Patients with more intense inflammation at randomization had better survival with PCSK9 inhibition vs placebo, indicating that inflammatory intensity may drive therapeutic benefits. (Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19 [IMPACT-SIRIO 5]; NCT04941105).
引用
- Navarese EP, Podhajski P, Gurbel PA, et al. PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection. J Am Coll Cardiol. 2023. PMID: 36653090. doi:10.1016/j.jacc.2022.10.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。